Volume 36, Issue 4, Pages (November 2009)

Slides:



Advertisements
Similar presentations
Essential Role of ERK Dimers in the Activation of Cytoplasmic but Not Nuclear Substrates by ERK-Scaffold Complexes  Berta Casar, Adán Pinto, Piero Crespo 
Advertisements

Volume 19, Issue 2, Pages (July 2005)
Volume 11, Issue 4, Pages (April 2003)
Takashi Tanaka, Michelle A. Soriano, Michael J. Grusby  Immunity 
Volume 36, Issue 5, Pages (December 2009)
Volume 33, Issue 2, Pages (January 2009)
Volume 61, Issue 5, Pages (March 2016)
Volume 15, Issue 19, Pages (October 2005)
Volume 23, Issue 6, Pages (December 2005)
Volume 142, Issue 7, Pages e6 (June 2012)
Volume 48, Issue 5, Pages (December 2012)
Volume 87, Issue 7, Pages (December 1996)
Volume 66, Issue 5, Pages e9 (June 2017)
Volume 22, Issue 5, Pages (May 2012)
Volume 35, Issue 1, Pages (July 2009)
Volume 23, Issue 1, Pages (July 2006)
UV-Induced RPA1 Acetylation Promotes Nucleotide Excision Repair
p53 Stabilization and Transactivation by a von Hippel-Lindau Protein
Yongli Bai, Chun Yang, Kathrin Hu, Chris Elly, Yun-Cai Liu 
Volume 28, Issue 2, Pages (August 2015)
Volume 56, Issue 1, Pages (October 2014)
Dana Chuderland, Alexander Konson, Rony Seger  Molecular Cell 
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Stefanie S. Schalm, Diane C. Fingar, David M. Sabatini, John Blenis 
Volume 150, Issue 4, Pages (August 2012)
Volume 29, Issue 3, Pages (February 2008)
Glucose-Induced β-Catenin Acetylation Enhances Wnt Signaling in Cancer
Calnexin Controls the STAT3-Mediated Transcriptional Response to EGF
Volume 150, Issue 4, Pages (August 2012)
Volume 29, Issue 4, Pages (February 2008)
Volume 31, Issue 4, Pages (August 2008)
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Volume 13, Issue 1, Pages (January 2008)
Volume 26, Issue 6, Pages (September 2013)
HDAC5, a Key Component in Temporal Regulation of p53-Mediated Transactivation in Response to Genotoxic Stress  Nirmalya Sen, Rajni Kumari, Manika Indrajit.
Ligand-Independent Recruitment of SRC-1 to Estrogen Receptor β through Phosphorylation of Activation Function AF-1  André Tremblay, Gilles B Tremblay,
C-Jun Downregulation by HDAC3-Dependent Transcriptional Repression Promotes Osmotic Stress-Induced Cell Apoptosis  Yan Xia, Ji Wang, Ta-Jen Liu, W.K.
Volume 45, Issue 6, Pages (March 2012)
Volume 22, Issue 2, Pages (April 2006)
Volume 17, Issue 2, Pages (January 2007)
Per Stehmeier, Stefan Muller  Molecular Cell 
Volume 56, Issue 5, Pages (December 2014)
Volume 53, Issue 1, Pages (January 2014)
GSK-3-Mediated Phosphorylation Enhances Maf-Transforming Activity
Lysine 63 Polyubiquitination of the Nerve Growth Factor Receptor TrkA Directs Internalization and Signaling  Thangiah Geetha, Jianxiong Jiang, Marie W.
c-Src Activates Endonuclease-Mediated mRNA Decay
Essential Role of TGF-β Signaling in Glucose-Induced Cell Hypertrophy
Volume 59, Issue 6, Pages (September 2015)
Extracellular Regulated Kinase Phosphorylates Mitofusin 1 to Control Mitochondrial Morphology and Apoptosis  Aswin Pyakurel, Claudia Savoia, Daniel Hess,
Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation
Volume 25, Issue 5, Pages (March 2007)
Kimita Suyama, Irina Shapiro, Mitchell Guttman, Rachel B. Hazan 
Volume 52, Issue 2, Pages (October 2013)
Mst1 Is an Interacting Protein that Mediates PHLPPs' Induced Apoptosis
Volume 63, Issue 2, Pages (July 2016)
Yap1 Phosphorylation by c-Abl Is a Critical Step in Selective Activation of Proapoptotic Genes in Response to DNA Damage  Dan Levy, Yaarit Adamovich,
Volume 125, Issue 4, Pages (May 2006)
Fan Yang, Huafeng Zhang, Yide Mei, Mian Wu  Molecular Cell 
Volume 13, Issue 15, Pages (August 2003)
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Volume 34, Issue 6, Pages (June 2009)
USP15 Negatively Regulates Nrf2 through Deubiquitination of Keap1
Volume 34, Issue 5, Pages (June 2009)
Volume 2, Issue 4, Pages (October 2002)
Volume 49, Issue 2, Pages (January 2013)
A Direct HDAC4-MAP Kinase Crosstalk Activates Muscle Atrophy Program
Volume 22, Issue 3, Pages (May 2006)
c-IAP1 Cooperates with Myc by Acting as a Ubiquitin Ligase for Mad1
Volume 31, Issue 5, Pages (September 2008)
Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of β-catenin, and enhanced tumor cell.
Presentation transcript:

Volume 36, Issue 4, Pages 547-559 (November 2009) EGF-Induced ERK Activation Promotes CK2-Mediated Disassociation of α-Catenin from β-Catenin and Transactivation of β-Catenin  Haitao Ji, Ji Wang, Heinz Nika, David Hawke, Susan Keezer, Qingyuan Ge, Bingliang Fang, Xuexun Fang, Dexing Fang, David W. Litchfield, Kenneth Aldape, Zhimin Lu  Molecular Cell  Volume 36, Issue 4, Pages 547-559 (November 2009) DOI: 10.1016/j.molcel.2009.09.034 Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 1 EGFR Activation Results in Disruption of β-Catenin and α-Catenin Complex and Promotes β-Catenin Transactivation (A and B) Immunoprecipitation of α-catenin was followed by immunoblotting with a β-catenin antibody. The indicated cell lines were treated with EGF (100 ng/ml) for the indicated time (A). The subcellular fractionation was prepared from A431 cells treated with EGF (100 ng/ml) for 6 hr (B). (C and D) A431 cells without (C) or with (D) transfection of FLAG-α-catenin were treated with EGF (100 ng/ml) for 10 or 24 hr (C) or 6 hr (D) and immunostained with the indicated antibodies. (E) The nuclear fractions (left panel) or total cell lysate (right panel) were prepared from 293T cells expressing EGFR with or without FLAG-α-catenin. The cells were treated with EGF (100 ng/ml) for 6 hr, and immunoblotting was performed with the indicated antibodies. (F–H) The luciferase activity was determined after cells were treated with EGF (100 ng/ml) for 8 hr; the relative levels of luciferase activity were normalized to the levels of untreated cells and to the levels of luciferase activity of the Renilla control plasmid (F and H). pCep4-EGFR with either TOP-FLASH or FOP-FLASH were cotransfected with or without FLAG-α-catenin into 293T cells (F). A431 cells were stably expressed with control shRNA or α-catenin shRNA, and immunoblotting analyses were performed with the indicated antibodies (G). TOP-FLASH or FOP-FLASH was transfected into A431 cells that were stably expressed with control shRNA or α-catenin shRNA (H). Data in (F) and (H) represent the mean ±SD of three independent experiments. Molecular Cell 2009 36, 547-559DOI: (10.1016/j.molcel.2009.09.034) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 2 CK2α Interacts with and Phosphorylates α-Catenin at S641 (A) α-catenin immunoprecipitated from EGF-stimulated A431 cells was analyzed with mass spectrometry. Mass spectrometric analysis of a tryptic fragment, 634-TPEELDDSDFETEDFDVR-651, indicates S641 was phosphorylated. The m/z difference between y-11 and y-10 matched with phospho-serine. (B–E) Immunoblotting analyses were performed with the indicated antibodies. In vitro kinase assays were performed with purified, bacterially expressed WT His-α-catenin or His-α-catenin S641A with or without CK2α (B). pRc/CMV2-HA-CK2α was cotransfected with pEGFP N1-FLAG-tagged WT α-catenin or α-catenin S641A mutant into 293T cells; immunoblotting of immunoprecipitated FLAG-tagged α-catenins with the anti-α-catenin S641 antibody was performed (C). The subcellular fractionation was prepared from A431 cells treated with EGF (100 ng/ml) for 30 min (D). A431 cells expressing FLAG-tagged WT α-catenin were treated with or without EGF (100 ng/ml) for 1 or 3 hr. CK2α was immunoprecipitated (E). (F) A431 cells with or without expression of CK2α shRNA or a control shRNA were treated with or without EGF (100 ng/ml) for 30 min. Molecular Cell 2009 36, 547-559DOI: (10.1016/j.molcel.2009.09.034) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 3 CK2α-Mediated Phosphorylation of α-Catenin at S641 Releases α-Catenin from Binding to β-Catenin (A–E) Immunoprecipitation and immunoblotting analyses were performed with the indicated antibodies. In vitro kinase assays were performed with purified, bacterially expressed WT His-α-catenin with or without CK2α, which is followed by GST pull-down analyses with GST (control) or GST-β-catenin glutathione-agarose beads (A). FLAG-tagged α-catenin was cotransfected with pRc/CMV2-HA-CK2α or pRc/CMV2-HA-CK2α K68M into 293T cells (B). A431 cells with or without expressing CK2α shRNA were treated with or without EGF (100 ng/ml) for 2 hr (C). FLAG-tagged WT α-catenin, α-catenin S641A, or α-catenin S641D mutant were transfected into 293T cells; immunoprecipitation of the total cell lysate with an anti-FLAG antibody was followed by immunoblotting analyses with the indicated antibodies (D). FLAG-tagged WT α-catenin, α-catenin S641A, or α-catenin S641D mutant were transfected into 293T cells, and immunoprecipitation of the membrane or nucleus fraction was performed with the indicated antibodies (E). Molecular Cell 2009 36, 547-559DOI: (10.1016/j.molcel.2009.09.034) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 4 ERK1/2 Phosphorylates CK2α and Enhances CK2α Activity toward α-Catenin in Response to EGF Stimulation (A) As shown in panels (A)–(H), immunoprecipitation and immunoblotting analyses were performed with the indicated antibodies. In (A), in vitro kinase assays were performed by mixing purified ERK2 or ERK5 with boiled CK2α. (B) In vitro kinase assays were performed by mixing purified ERK2 with boiled CK2α, CK2α T360A, CK2α S362A, or T360/S362A mutants. (C) 293T cells expressing MEK1 Q56P and ERK2 with FLAG-tagged WT CK2α or CK2α T360/S362A were metabolically labeled with 32P-phosphate for 12 hr. Immunoprecipitation with an anti-FLAG antibody was performed. (D) Purified CK2α with or without purified His-α-catenin (left panel) or HDAC3 (right panel) was mixed with purified ERK2 in kinase assays. The images were quantified by scanning densitometry. (E) In vitro kinase assays were performed by mixing nonboiled WT CK2α or CK2α K68M with or without purified ERK2. (F and G) MEK1 Q56P was cotransfected with WT ERK2 or ERK2 K52R kinase-dead mutant together with WT α-catenin or α-catenin S641A into 293T cells. The cells were treated without (F) or with TBB (40 μM) (G) for 6 hr before harvesting. (H) A431 or U373 cells were pretreated with U0126 (25 μM) or TBB (40 μM) for 30 min before EGF (100 ng/ml) stimulation for 30 min. Molecular Cell 2009 36, 547-559DOI: (10.1016/j.molcel.2009.09.034) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 5 ERK2 Directly Binds to CK2α through Its Docking Groove (A–C) Immunoprecipitation and immunoblotting analyses were performed with the indicated antibodies. Immobilized purified His-CK2α was mixed with purified ERK2, followed by washing three times with cell lysis buffer and immunoblotting analysis (A). Nickel-agarose beads were used as control. 293T cells were transfected with a control vector or vectors expressing MEK1 Q56P and FLAG-ERK2 (B). A vector expressing MEK1 Q56P was cotransfected with FLAG-WT ERK2, FLAG-ERK2 T/E (T157/158E), FLAG-ERK2 D/N (D316/319N), or FLAG-ERK2 T/E-D/N mutant into 293T cells (C). Molecular Cell 2009 36, 547-559DOI: (10.1016/j.molcel.2009.09.034) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 6 EGF-Induced ERK2 Activation Promotes β-Catenin Transactivation and Tumor Cell Invasion by Enhancing CK2-Phosphorylated α-Catenin at S641 (A–D) The relative levels of luciferase activity were normalized to the levels of untreated cells and to the levels of luciferase activity of the Renilla control plasmid. Data represent the mean ±SD of three independent experiments. TOP-FLASH or FOP-FLASH was cotransfected with or without the indicated plasmids into 293T cells (A). TOP-FLASH or FOP-FLASH was cotransfected with or without vectors expressing MEK1 Q56P and ERK2 into 293T cells, and the cells were pretreated with TBB (40 μM) for 6 hr before harvesting (B). As shown in (C), TOP-FLASH or FOP-FLASH was cotransfected with a vector expressing EGFR into 293T cells; the cells were pretreated with TBB (40 μM), apigenin (40 μM), U0126 (25 μM), or PD98059 (30 μM) for 30 min before EGF (100 ng/ml) for 6 hr (C). TOP-FLASH or FOP-FLASH was cotransfected with vectors expressing FLAG-tagged WT α-catenin, α-catenin S641A, or α-catenin S641D into A431 cells. The cells were treated with EGF (100 ng/ml) for 8 hr (D). Immunoblotting with indicated antibodies was performed (D, left upper panel). (E and F) A pool of A431 cells expressing a control shRNA or CK2α shRNA (E) or stably transfected with a vector, FLAG-tagged WT α-catenin, α-catenin S641A, or α-catenin S641D (F) was plated onto the top surface of the Matrigel in the absence or presence of EGF (100 ng/ml). One day after plating, cells that migrated to the opposite side of the insert were stained with crystal violet. Representative microphotographs are shown (left panel). The membranes with invaded cells were dissolved in 4% deoxycholic acid and read colorimetrically at 590 nm for quantification of invasion. Data represent the mean ±SD of three independent experiments (right panel). Immunoblotting with indicated antibodies was performed (right upper panel). Molecular Cell 2009 36, 547-559DOI: (10.1016/j.molcel.2009.09.034) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 7 Levels of α-Catenin S641 Phosphorylation Correlate with Levels of ERK1/2 Activity in Human GBM and with Grades of Glioma Malignancy (A) Immunohistochemical staining with anti-phospho-ERK1/2 and anti-phospho-α-catenin S641A antibodies was performed on 46 GBM specimens. Representative photos of four tumors were shown. (B) Immunohistochemical staining on the tissue sections was scored semiquantitatively as described in the Experimental Procedures (Pearson product moment correlation test r = 0.76; p < 0.0001). Note that some of the dots on the graphs represented more than one specimen (some scores overlapped). (C) Immunohistochemical staining of 23 diffuse astrocytoma specimens with an anti-phospho-α-catenin S641 antibody was performed and analyzed by comparing it with the staining of 46 GBM specimens (Student's t test, two-tailed, p < 0.000001). Data represent the mean ±SD of sample scores. Molecular Cell 2009 36, 547-559DOI: (10.1016/j.molcel.2009.09.034) Copyright © 2009 Elsevier Inc. Terms and Conditions